Evolent Health (NYSE:EVH) reported Q4 EPS of $0.10, in-line with the analyst estimate of $0.10. Revenue for the quarter came in at $382.43 million versus the consensus estimate of $372.93 million.
GUIDANCE:
Evolent Health sees Q1 2023 revenue of $420-440 million, versus the consensus of $410.1 million.
Evolent Health sees FY2023 revenue of $1.92-1.96 billion, versus the consensus of $1.882 billion.